title: Evaluation of ovarian function and metabolic factors in women affected by polycystic ovary syndrome after treatment with D-Chiro-Inositol.
abstract: OBJECTIVE
  To evaluate the effects of D-Chiro-Inositol in women affected by polycystic ovary syndrome (PCOS).
  
  
  METHODS
  We enrolled 48 patients, with homogeneous bio-physical characteristics, affected by PCOS and menstrual irregularities. These patients underwent treatment with 1 gr of D-Chiro-Inositol/die plus 400 mcg of Folic Acid/die orally for 6 months. We analyzed pre-treatment and post-treatment BMI, Systolic and Diastolic blood pressure, Ferriman-Gallwey score, Cremoncini score, serum LH, LH/FSH ratio, total and free testosterone, DHEA-S, Δ-4-androstenedione, SHBG, prolactin, glucose/IRI ratio, HOMA index, and resumption of regular menstrual cycles.
  
  
  RESULTS
  We evidenced a statistically significant reduction of systolic blood pressure, Ferriman-Gallwey score, LH, LH/FSH ratio, total Testosterone, free Testosterone, ∆-4-Androstenedione, Prolactin, and HOMA Index; in the same patients, we noticed a statistically significant increase of SHBG and Glycemia/IRI ratio. Moreover, we observed statistically significant (62.5%; p < 0.05) post-treatment menstrual cycle regularization.
  
  
  CONCLUSIONS
  D-Chiro-Inositol is effective in improving ovarian function and metabolism of patients affected by PCOS.
authors.affiliation: Department of Pediatric Gynecological, Microbiological and Biomedical Sciences, University of Messina, Via C. Valeria 1, 98125, Messina, Italy, antlagana@unime.it.
authors.forename: Antonio Simone
authors.initials: AS
authors.lastname: Laganà
authors.forename: Luisa
authors.initials: L
authors.lastname: Barbaro
authors.forename: Alfonsa
authors.initials: A
authors.lastname: Pizzo
mesh_terms: D000328:Adult; D001786:Blood Glucose; D005260:Female; D005492:Folic Acid / Q000008:administration & dosage* / Q000627:therapeutic use; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007294:Inositol / Q000494:pharmacology* / Q000627:therapeutic use; D007986:Luteinizing Hormone / Q000097:blood; D008597:Menstrual Cycle / Q000097:blood / Q000187:drug effects; D008599:Menstruation Disturbances / Q000097:blood / Q000188:drug therapy*; D008796:Metrorrhagia / Q000209:etiology / Q000517:prevention & control; D008875:Middle Aged; D009839:Oligomenorrhea / Q000209:etiology / Q000517:prevention & control; D010053:Ovary / Q000503:physiopathology*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D011388:Prolactin / Q000097:blood; D011446:Prospective Studies; D013739:Testosterone / Q000097:blood; D016896:Treatment Outcome; D014803:Vitamin B Complex / Q000494:pharmacology* / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D001786:Blood Glucose; D014803:Vitamin B Complex; D013739:Testosterone; D007294:Inositol; D011388:Prolactin; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone; D005492:Folic Acid